Holen Sie sich die Stockscreener-App
189.69
1.38%
-2.66
Handel nachbörslich:
187.97
-1.72
-0.91%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$192.35
Offen:
$191.44
24-Stunden-Volumen:
869.60K
Relative Volume:
0.88
Marktkapitalisierung:
$21.10B
Einnahmen:
$10.52B
Nettoeinkommen (Verlust:
$999.00M
KGV:
22.68
EPS:
8.3628
Netto-Cashflow:
$1.22B
1W Leistung:
+2.01%
1M Leistung:
+4.12%
6M Leistung:
+10.78%
1J Leistung:
+16.90%
1-Tages-Spanne:
$189.22
$192.25
1-Wochen-Bereich:
$186.25
$193.76
52-Wochen-Spanne:
$148.70
$197.55
Quest Diagnostics Inc Stock (DGX) Company Profile
Firmenname
Quest Diagnostics Inc
Sektor
Branche
Telefon
(973) 520-2700
Adresse
500 PLAZA DRIVE, SECAUCUS
Vergleichen Sie DGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
189.69 | 21.40B | 10.52B | 999.00M | 1.22B | 8.3628 |
|
TMO
Thermo Fisher Scientific Inc
|
593.25 | 224.59B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
228.46 | 163.00B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
755.96 | 61.22B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
154.37 | 44.50B | 6.95B | 1.30B | 1.09B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
231.80 | 39.50B | 15.90B | 1.28B | 2.21B | 7.2842 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-01-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | Jefferies | Buy |
| 2024-10-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Fortgesetzt | Evercore ISI | In-line |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-02-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-29 | Eingeleitet | Piper Sandler | Neutral |
| 2023-05-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-23 | Eingeleitet | Evercore ISI | In-line |
| 2022-11-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-23 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-02 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-28 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-03-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Hochstufung | Argus | Hold → Buy |
| 2020-07-29 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-09 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-04-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2019-04-02 | Hochstufung | Jefferies | Hold → Buy |
| 2019-03-18 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-01-31 | Herabstufung | Argus | Buy → Hold |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten
Should You Hold Quest Diagnostics Stock in Your Portfolio for Now? - Yahoo Finance
DGX Stock Up on New Blood Test Development Deal With MD Anderson - MSN
Is Quest Diagnostics Incorporated stock nearing a technical breakout2025 Analyst Calls & Technical Pattern Alert System - newser.com
Is Quest Diagnostics Incorporated (QDI) stock protected from inflationQuarterly Performance Summary & Expert Curated Trade Ideas - newser.com
How Quest Diagnostics Incorporated stock performs in rate cut cyclesQuarterly Portfolio Review & AI Driven Price Predictions - newser.com
Quest Diagnostics (DGX) Up 2.6% Since Last Earnings Report: Can It Continue? - sharewise.com
Quest Diagnostics Stock Outlook: Is Wall Street Bullish or Bearish? - Yahoo Finance
How Quest Diagnostics Incorporated stock valuations compare to rivalsQuarterly Earnings Summary & Verified Stock Trade Ideas - newser.com
Can Quest Diagnostics Incorporated (QDI) stock deliver strong annual returnsChart Signals & Real-Time Chart Pattern Alerts - newser.com
How Quest Diagnostics Incorporated stock benefits from global expansionTake Profit & Expert Curated Trade Setup Alerts - newser.com
Is Quest Diagnostics Incorporated (QDI) stock good for long term investingPortfolio Growth Summary & Consistent Profit Focused Trading Strategies - newser.com
Will Quest Diagnostics Incorporated stock profit from fiscal stimulus2025 AllTime Highs & Detailed Earnings Play Alerts - newser.com
Published on: 2025-11-19 23:07:04 - newser.com
Using flow based indicators on Quest Diagnostics IncorporatedJuly 2025 Outlook & Safe Capital Preservation Plans - newser.com
What Fibonacci levels say about Quest Diagnostics Incorporated reboundIPO Watch & Weekly Top Stock Performers List - newser.com
Published on: 2025-11-19 13:33:19 - newser.com
Is Quest Diagnostics Incorporated (QDI) stock positioned for secular growthPrice Action & Advanced Swing Trade Entry Plans - newser.com
Why analysts maintain buy rating on Quest Diagnostics Incorporated stockJuly 2025 Setups & Verified Technical Signals - newser.com
Will Quest Diagnostics Incorporated stock gain from lower inflationJuly 2025 Review & Safe Capital Investment Plans - newser.com
Published on: 2025-11-19 01:41:12 - newser.com
Why Quest Diagnostics Incorporated stock is a strong buy callMarket Weekly Review & High Conviction Buy Zone Picks - newser.com
Published on: 2025-11-19 00:41:47 - newser.com
Why millennials buy Quest Diagnostics Incorporated stock2025 Technical Overview & Safe Capital Growth Stock Tips - newser.com
Published on: 2025-11-18 23:34:07 - newser.com
Will Quest Diagnostics Incorporated (QDI) stock beat international competition - newser.com
Finanzdaten der Quest Diagnostics Inc-Aktie (DGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.58%
0.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):